SALE

Test Bank for Psychopharmacology for Mental Health Professionals An Integrative Approach, 2nd Edition

Original price was: $35.00.Current price is: $26.50.

Test Bank for Psychopharmacology for Mental Health Professionals An Integrative Approach, 2nd Edition Digital Instant Download

Category:

This is completed downloadable of Test Bank for Psychopharmacology for Mental Health Professionals An Integrative Approach, 2nd Edition

Product Details:

  • ISBN-10 ‏ : ‎ 1285845226
  • ISBN-13 ‏ : ‎ 978-1285845227
  • Author:  Elliott Ingersoll, Dr. Carl Rak

Master the basics of psychopharmacology with PSYCHOPHARMACOLOGY FOR MENTAL HEALTH PROFESSIONALS, Second Edition. Concise yet comprehensive, this counseling text covers the basic principles of psychopharmacology, commonly prescribed psychotropic drugs for adults, and psychotropic medications prescribed to children. Psychological, cultural, and social issues related to psychopharmacology are also addressed. Numerous case examples, study questions, bolded key terms, and a glossary help you understand and applying the material. Practical information about how to talk with clients about medication and compliance as well as hands-on information about how to approach collaboration with prescribing professionals prepares you to apply what you have learned to practice. This edition includes new material on psychosocial treatments that complement the most prescribed medications, expanded discussion of medication of children and the elderly, a new chapter on drug replacement therapies, reference to changes in the DSM-5, and more.

 

Table of Content:

  1. Part 1: An Overview of the New Edition
  2. Ch 1: Introduction
  3. Encouragement to the Reader
  4. A Mantra
  5. Scientific Truth and the Acceleration of Knowledge
  6. Chapter One: Section Two
  7. Psychopharmacology and Magical Thinking
  8. Moving on: What We Know, What We Do Not Know
  9. The Mind-Brain Problem
  10. The Layout of This Book
  11. Study Questions and Exercises
  12. Ch 2: Introduction to the Nervous System, Neurons, and Pharmacodynamics
  13. Introduction
  14. Section One: An Overview of Physiology Relevant to Psychopharmacology
  15. A Few Basics
  16. Section Two: Exploring the Central Nervous System
  17. Section Three: An Overview of Neurons and Glial Cells
  18. The Basic Anatomy of a Neuron
  19. Glial Cells
  20. The Blood-Brain Barrier
  21. Section Four: Types of Neurotransmitters
  22. Glutamate (Glu)
  23. Gamma-Aminobutyric Acid (GABA)
  24. Acetylcholine (Ach)
  25. Monoamine Neurotransmitters
  26. Dopamine (DA)
  27. Norepinephrine (NE)
  28. Serotonin (5-HT)
  29. Reality is Complex and …
  30. Section Five: The Story of Neurotransmission
  31. Neurotransmission: The Team Players
  32. Back to Neurotransmitters
  33. Ions
  34. Ion Channels
  35. A View within the Cell
  36. The Process of Neurotransmission
  37. First-Messenger Effects
  38. Second-Messenger Effects
  39. A Quick Review
  40. What Happens When Neurotransmitters Bind to Receptors?
  41. What Happens to the Released Neurotransmitter?
  42. Section Six: Pharmacodynamics or How Psychotropic Medications Affect Neurotransmission
  43. Agonism and Antagonism
  44. Mechanisms of Action with Effects on Production
  45. Mechanisms of Action with Effects on Release of Neurotransmitter
  46. Mechanisms of Action Targeting Neurotransmitter Deactivation
  47. Summary
  48. Case of Colleen
  49. Class Exercise: The Psychodramatic Neuron
  50. Study Questions and Exercises
  51. Ch 3: Pharmacokinetics: How the Body Acts on Psychotropic Medications
  52. Section One: Drug Absorption
  53. Section Two: Getting to the Bloodstream
  54. Section Three: Drug Distribution
  55. Section Four: Drug Binding and Types of Tolerance
  56. Section Five: Elimination of Drugs
  57. Case
  58. Ch 4: Psychological, Social, and Cultural Issues in Psychopharmacology
  59. Section One: Adherence and Compliance with Medication Regimens
  60. Client Reactions to the Medical Model of Mental Illness
  61. Compliance and Adherence
  62. Reasons that Clients May Not Comply
  63. Section Two: Talking to Clients about Medications: Know and Educate Thyself
  64. Specific Supervision Issues
  65. Assessment
  66. Monitoring
  67. Advocacy
  68. Summary
  69. Section Three: Ethno-Psychopharmacology: Group Differences in Response to Psychotropic Agents
  70. Sex Differences
  71. Racial Differences
  72. A Focus on the Cultural Perspective
  73. Case Study: The Case of Rafael
  74. Case
  75. A Meeting of Subcultures: Collaboration with Prescribing Professionals
  76. Section Four: Social Institutions and Their Impact on Psychotropic Medications
  77. Pharmacoeconomics
  78. Conclusion
  79. Summary
  80. Study Questions and Exercises
  81. Part 2: Introduction
  82. Ch 5: The Antidepressant Era
  83. Section One: The Current Impact of Antidepressants
  84. Major Depressive Disorder (MDD)
  85. Comorbidity of Depression and Anxiety
  86. Antidepressant Efficacy
  87. Section Two: Theories of Antidepressant Action
  88. Section Three: The Neurotrophic/Plasticity Hypothesis and New Theories of Antidepressant Action
  89. Newer Hypotheses and Theories
  90. Toward an Integrative Theory of Antidepressant Action
  91. Section Four: Overview of First-Generation Antidepressant Medications
  92. Tricyclic Antidepressants
  93. Section Five: Second Generation Antidepressants: Selective Serotonin Reuptake Inhibitors
  94. Psychological and Cultural Issues with SSRIs
  95. Section Six: Third-Generation Antidepressants
  96. Desvenlafaxine/Prestiq
  97. Brintellix/Vortioxetine
  98. Milnacipran/Savella
  99. Into the Future: Ketamine
  100. Summary Points about Antidepressants
  101. Case of Joshua
  102. Antidepressants in Older Clients
  103. Section Seven: Focus on Psychological, Cultural, and Social Perspectives
  104. Psychological Perspectives
  105. Different Perspectives on the Placebo Problem
  106. Other Treatments for Depression
  107. A Problem Case: The Case of Alex
  108. Summary
  109. Study Questions and Exercises
  110. Ch 6: The Age of Anxiety
  111. Section One: Overview of Anxiolytic Medication and the Construct of Anxiety
  112. Theories of Anxiolytic Action
  113. Section Two: The Central Nervous System: Anxiety, Brain Circuits, Brain Structures, and Neurotransmi
  114. Section Three: Central Nervous System Depressants
  115. Benzodiazepines
  116. Section Four: Nonbenzodiazepine Alternatives
  117. Hypnotics
  118. Buspirone: A Unique Anxiolytic
  119. Section Five: Newer Approaches to Anxiolytic Medications
  120. Section Six: SSRI Treatment of Anxiety
  121. Section Seven: Anxiolytic Therapy by Diagnosis
  122. Section Eight: Focus on Psychological, Cultural, and Social Issues
  123. Psychological Issues
  124. Summary
  125. Ch 7: Antipsychotic Medications: The Evolution of Treatment
  126. The Current Impact of Antipsychotics
  127. Section One: Schizophrenia
  128. Section Two: Theories of Neuroleptic Action from the Medical Model Perspective
  129. The Case of Colin
  130. The Case of Ethel
  131. The Case of Teana
  132. The Case of Maurice
  133. Section Four: Clozaril: The Prototype for Atypical Antipsychotics
  134. The Case of Bonnie
  135. A New Era
  136. Section Five: The Serotonin/Dopamine Antagonists
  137. The Case of Melanie
  138. Section Six: Newer Agents
  139. Section Seven: Focus on Other Perspectives
  140. Psychological Considerations
  141. Summary
  142. Ch 8: Mood Stabilizers
  143. Section One: Mood Misnomers
  144. Section Two: Bipolar I Disorder
  145. Section Three: Some History on Mood Stabilizers
  146. Section Four: Lithium: The Prototypical Mood Stabilizer
  147. Section Five: Anticonvulsants as Mood Stabilizers
  148. Oxcarbazepine/Trileptal
  149. The Case of Molly
  150. The Case of Roger
  151. Valproic Acid
  152. The Case of Jose
  153. The Case of Beverly
  154. Section Six: Newer Anticonvulsants as Mood Stabilizers
  155. Section Seven: Atypical Antipsychotics as Mood Stabilizers
  156. General Conclusions on Mood Stabilizers
  157. Section Seven: Issues from Other Perspectives
  158. Section Eight: Issues from the Cultural and Social Perspectives
  159. Conclusion
  160. Summary
  161. Part 3: Newer Issues
  162. Ch 9: Medicating Children
  163. Section One: Perspectives, Dilemmas, and Future Paradigms
  164. The Complex State of Therapy
  165. The Explosion of Psychotropic Medication Prescriptions for Children and Adolescents
  166. The Case of Phillip
  167. The Medication of Children and the Federal Laws
  168. A Word on Cross-Cultural Perspectives
  169. Psychological Perspectives of Children and Adolescents
  170. Opposition to the Current Trend of Medicating
  171. An Overview of Pediatric and Adolescent Psychopharmacology
  172. Section Two: Stimulant Medication
  173. Section Three: ADHD and Combined Interventions
  174. Section Four: Mood Stabilizers and Bipolar I Disorder in Children
  175. The Case of Nicole
  176. Section Five: Children and Antipsychotic Medication
  177. Section Six: Antianxiety Medications and Children and Adolescents
  178. School Issues, Anxiety, and Children
  179. Section Seven: Antidepressants and Children and Adolescents
  180. The Placebo Problem
  181. Conclusion
  182. Summary
  183. Ch 10: Herbaceuticals
  184. The Behavior of Herbaceutical Use
  185. Section One: Psychological Issues
  186. Section Two: Issues of Culture
  187. Section Three: Issues from the Social Perspective
  188. Section Four: Problems in Studying Medicinal Plants
  189. Differences between Herbs and Drugs
  190. Section Five: Examining Better Known Herbaceuticals with Application for Psychiatric Problems
  191. Section Six: An Integrative View of Marijuana
  192. Conclusions
  193. Summary
  194. Study Questions and Exercises
  195. Ch 11: Pharmacotherapy of Alcohol and Drug-Related Disorders
  196. Section One: Brief Historical Sketch of Pharmacological Treatments for Patients Experiencing Drug an
  197. Pharmacological Treatment of Alcoholism
  198. Pharmacological Treatment of Opioid Dependence
  199. Section Two: Current Statistical Impact of Drug and Alcohol Abuse/Dependency and Terminology
  200. Section Three: Pharmacological Treatment of Individuals with Alcohol-Use Disorders
  201. Disulfiram Treatment
  202. Naltrexone Treatment
  203. Acamprosate Treatment
  204. Combined Pharmacotherapy
  205. Additional Pharmacotherapies for Alcohol-Use Disorders
  206. Section Four: Pharmacotherapy of Individuals Diagnosed with Severe Opioid Dependence
  207. Methadone Maintenance Treatment (MMT)
  208. Naltrexone Pharmacotherapy
  209. Buprenorphine Treatment
  210. Buprenorphine/Naloxone Treatment (Bup/Nx)
  211. Section Five: Cultural Considerations for Treating Patients, Pharmacologically, with Substance-Use D
  212. Stigmatization of Substance-Use Addiction and Treatment
  213. Multicultural Competent Practice and Advocacy
  214. A Problem Case: The Case of Carlos
  215. Clinical Recommendations
  216. Summary
  217. Study Questions and Exercises
  218. Ch 12: Drug-Assisted Psychotherapy
  219. Introduction
  220. What Do Psilocybin and MDMA Do?
  221. Hallucinogen Terminology over Time
  222. The Subjective Effects of Psilocybin
  223. The Subjective Effects of MDMA
  224. Clinical Research with Psilocybin and MDMA
  225. The Nature of Early Drug-Assisted Psychotherapy Research
  226. Set and Setting
  227. Psilocybin-Assisted Psychotherapy in Brief
  228. MDMA-Assisted Psychotherapy for Post-Traumatic Stress Disorder
  229. Healthy Volunteer Research
  230. The Use of MDMA and Hallucinogens in Clinical Training
  231. Mechanisms of Action
  232. Is It the Drug, the Psychotherapy, or Both?
  233. Clinical Effect without Psychotherapy
  234. Between Psychopharmacology and Psychotherapy
  235. Risks versus Benefits
  236. Ch 13: Psychotropic Medication and the Elderly
  237. Introduction: The New Old Age
  238. Section One: DSM-5 Changes to Delirium and Dementia
  239. Medications for Alzheimer’s Disease and Parkinson’s Disease
  240. Can Alzheimer’s Disease Be Prevented?
  241. Acetylcholinesterase Inhibitors
  242. Section Two: The State of Psychosocial Interventions for Elderly Clients
  243. Section Three: Pharmacologic Treatment of Dementia: From the 20th Century and into the 21st Century
  244. Commonly Prescribed Psychotropic Medications in Elderly Population
  245. Depression
  246. Anxiety
  247. Psychosis/Agitation
  248. Section Four: Aging and Assisted Living
  249. Section Five: Side Effects Peculiar to the Elderly
  250. Psychotropic Side/Adverse Effects in Elderly Clients
  251. Glossary
  252. References
  253. Name Index
  254. Subject Index

Related products